Navigation Links
COURAGE Sub-study: PCI Outperforms Drugs-Only

PCI Provides Patients With Clogged Arteries Significant Added Benefits Over

Drugs, According to Nuclear Imaging Scans

WASHINGTON, Nov. 6 /PRNewswire/ -- Patients with ischemia, or clogged arteries, benefit significantly from percutaneous coronary intervention (PCI) when compared with optimal medical therapy, according to a nuclear sub-study of the COURAGE trial presented this week at the American Heart Association (AHA) in Orlando.

This sub-study is especially significant given that the COURAGE trial had previously called into question the relative effectiveness of PCI (which uses a combination of angioplasty, stents, and medications) compared to medications alone in the prevention of death and heart attack in patients with stable heart disease.

The Society for Cardiovascular Angiography and Interventions (SCAI), the world's leading society of interventional cardiologists, questioned those findings from the beginning. SCAI noted that the COURAGE study excluded all but the most stable patients, including only those who were able to adhere to very strict medication and lifestyle-change requirements. COURAGE also enrolled patients only after their anatomy was determined, another significant study design limitation. Furthermore, the existing data had never suggested that angioplasty or stenting reduced the risk of death or heart attack in this population of stable patients.

"This new analysis confirms what interventional cardiologists have said all along -- when compared to using only drugs, PCI improves overall heart health and reduces debilitating chest pain by opening up blocked arteries," said Dr. Bonnie Weiner, President of The Society for Cardiovascular Angiography and Interventions.

Patients with stable coronary artery disease, especially those with a moderate to severe case, gained significant long-term health benefits from PCI when compared with a drugs-only approach, according to Dr. Leslee J. Shaw, the principal investigator and a professor of medicine at Emory University, who presented the late-breaking clinical trial at the AHA Scientific Sessions.

Using a nuclear imaging technique called "single photon emission computed tomography" (SPECT), the study showed that patients with moderate to severe ischemia benefited most from PCI when compared with those who received only optimal medical therapy. In fact, when ischemia was reduced, the risk of death was also reduced. This finding confirms cardiologists' general understanding of heart disease -- that significant ischemia is not in a patient's best long- term interests.

The SPECT images, which enable physicians to assess the blood flow to the heart, showed that some patients had a very significant reduction in ischemia (more than 5 percent). Of patients who underwent PCI and took medications, 33 percent showed a reduction in ischemia of 5 percent or more, compared with only 19 percent of patients who took only medications.

"This study also confirms the importance of identifying patients who are at most risk and who can therefore most benefit from PCI," Dr. Weiner said.

Among the patients who had reduced ischemia, nearly 80 percent of both treatment groups were free of angina, which is characterized by chest pain that can be debilitating. PCI in addition to medications is clearly more effective than a medications-only approach in patients with high-risk ischemia (those with greater than 5 percent of their heart muscle compromised), according to the study.

The COURAGE trial received widespread attention earlier this year when some concluded that PCI offered no reduction in the risk of death or heart attack in patients with stable coronary artery disease compared with using only drugs.

The overall COURAGE trial looked at a narrow group of relatively healthy, stable patients who represented only about 30 percent of patients treated by interventional cardiologists. The nuclear sub-study demonstrates that even in these patients, the continued presence of ischemia increases the risks of death or heart attack. These risks can be reduced with revascularization.

For almost all other patients seen by interventional cardiologists, PCI is the preferred treatment, especially in heart attack patients, because it stops the heart attack immediately, saves lives, and improves health.

The COURAGE trial did not consider that many patients are not suitable for a medications-only approach because, although that approach may be desirable and recommended, such patients may not be able to tolerate side effects of the drugs or adhere to the strict regimen required due to multiple factors.

The COURAGE trial also did not address significant quality-of-life factors for the stable angina population. In consultation with their physicians, many patients choose PCI because it offers almost immediate relief from pain and discomfort, and they are much more likely to be able to resume normal lifestyle activities sooner with far fewer symptoms than many patients who choose the medications-only route.

If you are interested in reading more about the presentation of this nuclear sub-study, click on this link: ctn r2a.2007

If you are interested in learning more about the spectrum of care that interventional cardiologists use for evaluating treatment options for patients, click this link:


Headquartered in Washington, DC, the Society for Cardiovascular Angiography and Interventions is a 4,000-member professional organization representing invasive and interventional cardiologists in 70 nations. SCAI's mission is to promote excellence in invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. SCAI's annual meeting has become the leading venue for education, discussion, and debate about the latest developments in this dynamic medical specialty.

SOURCE Society for Cardiovascular Angiography and Interventions(SCAI)
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic
3. New York City Cancer Patients, Survivors and Care Givers Encouraged to Keep Going(R)
4. AARP Calls on Governor Schwarzenegger to Discourage Veto of SCHIP Expansion Bill
5. Standard treatment for prostate cancer may encourage spread of disease
6. Smilebox and Lifetime Television Promote Breast Cancer Awareness With Multimedia Designs for Sending Mammogram Reminders and Celebrating Courage
7. New Low-Back Pain Guidelines Should Encourage Patients to Utilize Spinal Manipulation
8. As Cold & Flu Season Nears, New Baby Nasal Aspirator Offers Safe and Effective Alternative to FDA-Discouraged Medicines
9. Independence Blue Cross Announces No Pay Getaway Promotion Designed to Encourage Healthy Behaviors
10. Parents Encouraged to Set an Example for Their Teens and Help Stop Underage Drinking
11. Amarillo Native Honored for Courage, Selflessness
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... facilities, radiographic technicians must mark the film for accurate interpretation by the radiologist. ... of. Fortunately, an inventor from Sacramento, Calif., has found a way to alleviate ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates mobile imaging results ... subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they are demonstrating new ... America (RSNA) 2015 annual meeting through December 3 in Chicago, Illinois, at Booth ...
(Date:12/1/2015)... ... 2015 , ... Next IT Healthcare, the leader in patient ... year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher of ... the category of Digital Solutions for its innovative, industry-leading product, Alme Health Coach. ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, ... in the United States. Clarity is a Superior Dual Wavelength Platform which combines ... single platform that is easy to own and operate. , For over a ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest white paper, ... addresses a main “pain point” for merging or aligning healthcare provider organizations—when mergers ... is signed. This quick-read guidance suggests that failing to recognize the power ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 01, 2015 ... addition of the "Medium Molecular Weight ... Lubricants, and Other Applications - Global Industry ... 2015 - 2023" report to their ... announced the addition of the "Medium ...
(Date:12/1/2015)... AMSTERDAM , Dec. 1, 2015 /PRNewswire/ -- ... announced SkyFlow , an X-ray imaging software that ... clinicians decide not to use a grid, at the ... (RSNA) 1 . SkyFlow is Philips, first digital ... for grid-less radiography, which improves clinician,s workflow and supports ...
(Date:12/1/2015)... WASHINGTON , Dec. 1, 2015  Athletic ... its founder have agreed to pay $1.35 million ... deceptively advertised the company,s copper-infused compression clothing would ... by arthritis and other diseases. ... also requires the company and its founder and ...
Breaking Medicine Technology: